|
|
|
Volumn 33, Issue 9, 2001, Pages
|
|
Practical considerations for pharmacogenetic testing.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOCHROME P450 2D6;
METHYLTRANSFERASE;
THIOPURINE METHYLTRANSFERASE;
ARTICLE;
CONTINUING EDUCATION;
COST BENEFIT ANALYSIS;
DRUG THERAPY;
ECONOMICS;
GENETIC POLYMORPHISM;
GENETIC SCREENING;
GENETICS;
HUMAN;
METABOLISM;
PHARMACOGENETICS;
STANDARD;
TREATMENT OUTCOME;
UNITED STATES;
COST-BENEFIT ANALYSIS;
CYTOCHROME P-450 CYP2D6;
DRUG THERAPY;
EDUCATION, CONTINUING;
GENETIC SCREENING;
HUMANS;
METHYLTRANSFERASES;
PHARMACOGENETICS;
POLYMORPHISM, GENETIC;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 0035461590
PISSN: 05807247
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
